Role of gemcitabine in the treatment of ovarian cancer

The US FDA has recently approved the combination of carboplatin and gemcitabine as a second-line therapy for recurrent platinum-sensitive ovarian cancer. This article briefly reviews the pharmacokinetics and mechanism of action of gemcitabine and its synergistic effect with platinum. An overview of...

Full description

Saved in:
Bibliographic Details
Published in:Women's health (London, England) England), 2007-05, Vol.3 (3), p.279-290
Main Authors: AbuShahin, Fadi, Rose, Peter G
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Cancer
carboplatin
Chemotherapy
cisplatin
Development and progression
gemcitabine
Ovarian cancer
paclitaxel
recurrent ovarian cancer
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The US FDA has recently approved the combination of carboplatin and gemcitabine as a second-line therapy for recurrent platinum-sensitive ovarian cancer. This article briefly reviews the pharmacokinetics and mechanism of action of gemcitabine and its synergistic effect with platinum. An overview of the literature on the role of gemcitabine in the treatment of epithelial ovarian cancer is also presented.
ISSN:1745-5057
1745-5065
DOI:10.2217/17455057.3.3.279